ABEONA THERAPEUTICS INC. (ABEO) research
ABEONA THERAPEUTICS INC.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $5.03
- As of
ABEONA THERAPEUTICS INC. (ABEO): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-15.
As of . Source: SEC EDGAR filings for ABEO. Method and limitations.
Share the ABEO intelligence card
See the full ABEO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ABEO on one page. Preview it with sample data, then open it live with a free account.
Preview the ABEO dossierActive signals for ABEO
- highCONSENSUS_BUY
3 tracked funds increased ABEO this 2026Q2, institutional consensus
- mediumtrend_spike
ABEONA THERAPEUTICS INC. search volume spiked +100 pts, unusual interest
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 50% of ABEO (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +209% to ABEO (2026Q2)
- mediumNEW_POSITION
TWO SIGMA INVESTMENTS, LP new position in ABEO
FREE, NO ACCOUNT
Every signal on ABEO, as it fires
You are seeing 5 of 9 signals recorded on ABEO since 2026-05-16.
The five above landed across 3 days. The other 4 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ABEO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 00289Y206 · 2026Q2 | $1.6M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 00289Y206 · 2026Q2 | $1.3M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 00289Y206 · 2026Q2 | $499K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 00289Y206 · 2026Q2 | $353K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ABEO
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ABEO against its peers
ABEO's operating margin of -1536.9% ranks in the 32nd percentile of 13 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-05-31.
| Metric | ABEO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 5.8M USD | 22.2M USD | 30 | 14 |
| Operating margin | -1536.9% | -623.6% | 32 | 13 |
| Net margin | 1223.1% | -634.6% | 97 | 14 |
| Return on equity | 44.7% | -54.2% | 93 | 20 |
| P / E | 5.0x | n/a | n/a | 1 |
Peers (23): RCKT, IPSC, EYPT, VNDA, XFOR, IKT, FATE, UPB, LXEO, QTTB, CYDY, PRLD, SABS, ACIU, EVMN, GLSI, IMRX, STRO, LRMR, CABA, NWBO, ANIK, IFRX. Left out: CUVL (no annual filing), VCRE (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (ABEO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ABEO signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ABEOand get the insider, 13F, options, and confluence read in one view.